|
DGAP-News: M1 Kliniken AG
/ Key word(s): Quarterly / Interim Statement/Development of Sales
M1 Kliniken AG continues successful development in Q4 2021
Berlin, 3.12.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) can look back on another successful month. After a peak value of average daily sales was achieved in October 2021 in the German practice network, this value was exceeded again in November 2021. Currently, all M1 specialist centres are open. The resolutions of Germany's Prime Minister's Conference yesterday also do not create any further restrictions for M1. At the same time, M1 clearly focuses on safety. All employees undergo a daily Corona test routine. From Dec. 6, 2021, a 3G regulation will also be implemented for patients. Four more specialist centres are to open in December 2021. With locations in Aachen, Potsdam and Würzburg the number of German specialist centres rises to 34. The third specialist centre in Australia, Brisbane, is scheduled to open before Christmas. The next target of 50 specialist centres is expected to be reached in the first quarter of 2022. About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical area, the group of companies offers products and services with the highest quality standards. Under the "M1 Med Beauty" brand, beauty medical treatments are currently offered at more than 40 specialist centres. In this context, the M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its investment in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of the treatment products in the medical-aesthetic field. Contact:M1 Kliniken AG Dr. Walter von Horstig, Management Board Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
03.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1253863 |
| End of News | DGAP News Service |
|
|
1253863 03.12.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
